LEGISLATURE OF NEBRASKA

ONE HUNDRED SIXTH LEGISLATURE

FIRST SESSION

LEGISLATIVE BILL 556

FINAL READING

Introduced by Howard, 9; Lindstrom, 18; Briese, 41.

Read first time January 22, 2019

Committee: Health and Human Services

- A BILL FOR AN ACT relating to prescription drugs; to amend section 1 71-2454, Reissue Revised Statutes of Nebraska, and sections 28-473, 2 3 28-474, and 38-101, Revised Statutes Cumulative Supplement, 2018; to transfer provisions to the Uniform Credentialing Act; to change duties for practitioners related to certain prescriptions; to exempt 5 certain prescriptions from requirements; to change provisions 6 7 relating to the prescription drug monitoring program; to define and 8 redefine terms; to eliminate obsolete provisions; to harmonize 9 provisions; to repeal the original sections; and to declare an 10 emergency.
- 11 Be it enacted by the people of the State of Nebraska,

LB556 2019 LB556 2019

1 Section 1. Section 38-101, Revised Statutes Cumulative Supplement,

- 2 2018, is amended to read:
- 3 38-101 Sections 38-101 to 38-1,142 and sections 2 and 3 of this act
- 4 and the following practice acts shall be known and may be cited as the
- 5 Uniform Credentialing Act:
- 6 (1) The Advanced Practice Registered Nurse Practice Act;
- 7 (2) The Alcohol and Drug Counseling Practice Act;
- 8 (3) The Athletic Training Practice Act;
- 9 (4) The Audiology and Speech-Language Pathology Practice Act;
- 10 (5) The Certified Nurse Midwifery Practice Act;
- 11 (6) The Certified Registered Nurse Anesthetist Practice Act;
- 12 (7) The Chiropractic Practice Act;
- 13 (8) The Clinical Nurse Specialist Practice Act;
- 14 (9) The Cosmetology, Electrology, Esthetics, Nail Technology, and
- 15 Body Art Practice Act;
- 16 (10) The Dentistry Practice Act;
- 17 (11) The Dialysis Patient Care Technician Registration Act;
- 18 (12) The Emergency Medical Services Practice Act;
- 19 (13) The Environmental Health Specialists Practice Act;
- 20 (14) The Funeral Directing and Embalming Practice Act;
- 21 (15) The Genetic Counseling Practice Act;
- 22 (16) The Hearing Instrument Specialists Practice Act;
- 23 (17) The Licensed Practical Nurse-Certified Practice Act until
- 24 November 1, 2017;
- 25 (18) The Massage Therapy Practice Act;
- 26 (19) The Medical Nutrition Therapy Practice Act;
- 27 (20) The Medical Radiography Practice Act;
- 28 (21) The Medicine and Surgery Practice Act;
- 29 (22) The Mental Health Practice Act;
- 30 (23) The Nurse Practice Act;
- 31 (24) The Nurse Practitioner Practice Act;

- 1 (25) The Nursing Home Administrator Practice Act;
- 2 (26) The Occupational Therapy Practice Act;
- 3 (27) The Optometry Practice Act;
- 4 (28) The Perfusion Practice Act;
- 5 (29) The Pharmacy Practice Act;
- 6 (30) The Physical Therapy Practice Act;
- 7 (31) The Podiatry Practice Act;
- 8 (32) The Psychology Practice Act;
- 9 (33) The Respiratory Care Practice Act;
- 10 (34) The Surgical First Assistant Practice Act;
- 11 (35) The Veterinary Medicine and Surgery Practice Act; and
- 12 (36) The Water Well Standards and Contractors' Practice Act.
- 13 If there is any conflict between any provision of sections 38-101 to
- 14 38-1,142 and sections 2 and 3 of this act and any provision of a practice
- 15 act, the provision of the practice act shall prevail.
- The Revisor of Statutes shall assign the Uniform Credentialing Act,
- 17 including the practice acts enumerated in subdivisions (1) through (35)
- 18 of this section, to articles within Chapter 38.
- 19 Sec. 2. Section 28-473, Revised Statutes Cumulative Supplement,
- 20 2018, is amended to read:
- 21 28-473 (1) For purposes of this section, practitioner means a
- 22 physician, a physician assistant, a dentist, a pharmacist, a podiatrist,
- 23 <u>an optometrist, a certified nurse midwife, a certified registered nurse</u>
- 24 <u>anesthetist</u>, and a nurse practitioner.
- 25 (2) (1) When prescribing a controlled substance listed in Schedule
- 26 II of section 28-405 or any other opiate <u>as defined in section 28-401</u> not
- 27 listed in Schedule II, prior to issuing the practitioner's initial
- 28 prescription for a course of treatment for acute or chronic pain—and
- 29 again prior to the practitioner's third prescription for such course of
- 30 treatment, a practitioner involved in the course of treatment as the
- 31 primary prescribing practitioner or as a member of the patient's care

- 1 team who is under the direct supervision or in consultation with the
- 2 <u>primary prescribing practitioner</u> shall discuss with the patient, or the
- 3 patient's parent or guardian if the patient is younger than eighteen
- 4 years of age and is not emancipated, unless the discussion has already
- 5 <u>occurred with another member of the patient's care team within the</u>
- 6 previous sixty days:
- 7 (a) The risks of addiction and overdose associated with the
- 8 controlled substance or opiate being prescribed, including, but not
- 9 limited to:
- 10 (i) Controlled substances and opiates are highly addictive even when
- 11 taken as prescribed;
- 12 (ii) There is a risk of developing a physical or psychological
- 13 dependence on the controlled substance or opiate; and
- 14 (iii) Taking more controlled substances or opiates than prescribed,
- 15 or mixing sedatives, benzodiazepines, or alcohol with controlled
- 16 substances or opiates, can result in fatal respiratory depression;
- 17 (b) The reasons why the prescription is necessary; and
- 18 (c) Alternative treatments that may be available.
- 19 (3) This section does not apply to a prescription for a hospice
- 20 patient or for a course of treatment for cancer or palliative care.
- 21 (4) (2) This section terminates on January 1, 2029.
- 22 Sec. 3. Section 28-474, Revised Statutes Cumulative Supplement,
- 23 2018, is amended to read:
- 24 28-474 (1) For purposes of this section, practitioner means a
- 25 physician, a physician assistant, a dentist, a pharmacist, a podiatrist,
- 26 <u>an optometrist, a certified nurse midwife, a certified registered nurse</u>
- 27 <u>anesthetist</u>, and a nurse practitioner.
- 28 (2) (1) The Legislature finds that:
- 29 (a) In most cases, acute pain can be treated effectively with
- 30 nonopiate or nonpharmacological options;
- 31 (b) With a more severe or acute injury, short-term use of opiates

- 1 may be appropriate;
- 2 (c) Initial opiate prescriptions for children should not exceed
- 3 seven days for most situations, and two or three days of opiates will
- 4 often be sufficient;
- 5 (d) If a patient needs medication beyond three days, the prescriber
- 6 should reevaluate the patient prior to issuing another prescription for
- 7 opiates; and
- 8 (e) Physical dependence on opiates can occur within only a few weeks
- 9 of continuous use, so great caution needs to be exercised during this
- 10 critical recovery period.
- 11 (3) (2) A practitioner who is prescribing an opiate <u>as defined in</u>
- 12 <u>section 28-401</u> for a patient younger than eighteen years of age for
- 13 outpatient use for an acute condition shall not prescribe more than a
- 14 seven-day supply except as otherwise provided in subsection (4) (3) of
- 15 this section and, if the practitioner has not previously prescribed an
- 16 opiate for such patient, shall discuss with a parent or guardian of such
- 17 patient, or with the patient if the patient is an emancipated minor, the
- 18 risks associated with use of opiates and the reasons why the prescription
- 19 is necessary.
- 20 (4) $\frac{(3)}{(3)}$ If, in the professional medical judgment of the
- 21 practitioner, more than a seven-day supply of an opiate is required to
- 22 treat such patient's medical condition or is necessary for the treatment
- 23 of pain associated with a cancer diagnosis or for palliative care, the
- 24 practitioner may issue a prescription for the quantity needed to treat
- 25 such patient's medical condition or pain. The practitioner shall document
- 26 the medical condition triggering the prescription of more than a seven-
- 27 day supply of an opiate in the patient's medical record and shall
- 28 indicate that a nonopiate alternative was not appropriate to address the
- 29 medical condition.
- 30 <u>(5)</u> (4) This section does not apply to controlled substances
- 31 prescribed pursuant to section 28-412.

- 1 (6) (5) This section terminates on January 1, 2029.
- 2 Sec. 4. Section 71-2454, Reissue Revised Statutes of Nebraska, is
- 3 amended to read:
- 4 71-2454 (1) An entity described in section 71-2455 shall establish a
- 5 system of prescription drug monitoring for the purposes of (a) preventing
- 6 the misuse of controlled substances that are prescribed, and (b) allowing
- 7 prescribers and dispensers to monitor the care and treatment of patients
- 8 for whom such a prescription drug is prescribed to ensure that such
- 9 prescription drugs are used for medically appropriate purposes, (c)
- 10 providing information to improve the health and safety of patients, and
- 11 <u>(d) ensuring</u> and that the State of Nebraska remains on the cutting edge
- 12 of medical information technology.
- 13 (2) Such system of prescription drug monitoring shall be implemented
- 14 as follows: Except as provided in subsection (4) of this section,
- 15 beginning January 1, 2017, all dispensed prescriptions of controlled
- 16 substances shall be reported; and beginning January 1, 2018, all
- 17 prescription drug information shall be reported to the prescription drug
- 18 monitoring system. The prescription drug monitoring system shall include,
- 19 but not be limited to, provisions that:
- 20 (a) Prohibit any patient from opting out of the prescription drug
- 21 monitoring system;
- 22 (b) Require <u>any prescription drug that is</u> all prescriptions
- 23 dispensed in this state or to an address in this state to be entered into
- 24 the system by the dispenser or his or her designee daily after such
- 25 prescription <u>drug</u> is dispensed, including <u>prescription drugs</u> those for
- 26 patients paying cash for such prescription drug or otherwise not relying
- 27 on a third-party payor for payment for the prescription drug;
- 28 (c) Allow all prescribers or dispensers of prescription drugs to
- 29 access the system at no cost to such prescriber or dispenser;
- 30 (d) Ensure that such system includes information relating to all
- 31 payors, including, but not limited to, the medical assistance program

- 1 established pursuant to the Medical Assistance Act; and
- 2 (e) Make the prescription <u>drug</u>information available to the
- 3 statewide health information exchange described in section 71-2455 for
- 4 access by its participants if such access is in compliance with the
- 5 privacy and security protections set forth in the provisions of the
- 6 federal Health Insurance Portability and Accountability Act of 1996,
- 7 Public Law 104-191, and regulations promulgated thereunder, except that
- 8 if a patient opts out of the statewide health information exchange, the
- 9 prescription drug information regarding that patient shall not be
- 10 accessible by the participants in the statewide health information
- 11 exchange.
- 12 Dispensers may begin on February 25, 2016, to report dispensing of
- 13 prescriptions to the entity described in section 71-2455 which is
- 14 responsible for establishing the system of prescription drug monitoring.
- 15 (3) Except as provided in subsection (4) of this section,
- 16 prescription <u>drug</u> information that shall be submitted electronically to
- 17 the prescription drug monitoring system shall be determined by the entity
- described in section 71-2455 and shall include, but not be limited to:
- 19 (a) The patient's name, address, <u>telephone number</u>, <u>if a telephone</u>
- 20 <u>number is available, gender, and date of birth;</u>
- 21 (b) A patient identifier such as a military identification number,
- 22 driver's license number, state identification card number, or other valid
- 23 government-issued identification number, insurance identification number,
- 24 pharmacy software-generated patient-specific identifier, or other
- 25 identifier associated specifically with the patient;
- 26 (c) (b) The name and address of the pharmacy dispensing the
- 27 prescription drug;
- 28 (d) (c) The date the prescription is issued;
- 29 (e) (d) The date the prescription is filled;
- 30 (f) The number of refills authorized;
- 31 (g) (e) The prescription number name of the prescription drug;

- 1 dispensed
- 2 <u>(h) The</u> or the National Drug Code number as published by the federal
- 3 Food and Drug Administration of the <u>prescription</u> drug <u>dispensed</u>;
- 4 (i) (f) The strength of the <u>prescription</u> drug prescribed;
- 5 <u>(j)</u> The quantity of the <u>prescription</u> drug prescribed and the
- 6 number of days' supply; and
- 7 $\frac{(k)}{(h)}$ The prescriber's name and National Provider Identifier
- 8 number or Drug Enforcement Administration number when reporting a
- 9 controlled substance.
- 10 (4) Beginning July 1, 2018, a veterinarian licensed under the
- 11 Veterinary Medicine and Surgery Practice Act shall be required to report
- 12 <u>the dispensing of</u> a <u>dispensed</u> prescription <u>drugs which are</u> of controlled
- 13 substances listed on Schedule II, Schedule III, Schedule IV, or Schedule
- 14 <u>V</u> IV pursuant to section 28-405. Each such veterinarian shall indicate
- 15 that the prescription is an animal prescription and shall include the
- 16 following information in such report:
- 17 (a) The first and last name and address, including city, state, and
- 18 zip code, of the individual to whom the <u>prescription</u> drug is dispensed in
- 19 accordance with a valid veterinarian-client-patient relationship;
- 20 (b) Reporting status;
- 21 (c) The first and last name of the prescribing veterinarian and his
- 22 or her federal Drug Enforcement Administration number;
- 23 (d) The National Drug Code number as published by the federal Food
- 24 <u>and Drug Administration</u> name of the <u>prescription</u> drug dispensed and the
- 25 prescription number;
- 26 (e) The date the prescription is written and the date the
- 27 prescription is filled;
- 28 (f) The number of refills authorized, if any; and
- 29 (g) The quantity of the <u>prescription</u> drug dispensed and the number
- 30 of days' supply.
- 31 (5)(a) All prescription drug information submitted pursuant to this

- 1 section, all data contained in the prescription drug monitoring system,
- 2 and any report obtained from data contained in the prescription drug
- 3 monitoring system are confidential, are privileged, are not public
- 4 records, and may be withheld pursuant to section 84-712.05 except for
- 5 <u>information released as provided in subsection (9) of this section</u>.
- 6 (b) No patient-identifying data as defined in section 81-664,
- 7 including the data collected under subsection (3) of this section, shall
- 8 be disclosed, made public, or released to any public or private person or
- 9 entity except to the statewide health information exchange described in
- 10 section 71-2455 and its participants, and to prescribers and dispensers
- 11 as provided in subsection (2) of this section, or as provided in
- 12 <u>subsection (7) of this section</u>.
- (c) All other data is for the confidential use of the department and
- 14 the statewide health information exchange described in section 71-2455
- 15 and its participants. The department, or the statewide health information
- 16 exchange in collaboration with the department, may release such
- 17 information as Class I, Class II, or Class IV data in accordance with
- 18 section 81-667 to the private or public persons or entities that the
- 19 department determines may view such records as provided in sections
- 20 81-663 to 81-675. In addition, the department, or the statewide health
- 21 information exchange in collaboration with the department, may release
- 22 such information as provided in subsection (9) of this section.
- 23 (6) The statewide health information exchange described in section
- 24 <u>71-2455</u>, in collaboration with the department, shall establish the
- 25 <u>minimum administrative</u>, physical, and technical safeguards necessary to
- 26 protect the confidentiality, integrity, and availability of prescription
- 27 <u>drug information</u>.
- 28 (7) If the entity receiving the prescription drug information has
- 29 privacy protections at least as restrictive as those set forth in this
- 30 section and has implemented and maintains the minimum safeguards required
- 31 by subsection (6) of this section, the statewide health information

7

exchange described in section 71-2455, in collaboration with the 1

- 2 department, may release the prescription drug information and any other
- 3 data collected pursuant to this section to:
- (a) Other state prescription drug monitoring programs; 4
- (b) State and regional health information exchanges; 5
- (c) The medical director and pharmacy director of the Division of 6
- Medicaid and Long-Term Care of the department, or their designees; (d) The medical directors and pharmacy directors of medicaid-managed 8
- 9 care entities, the state's medicaid drug utilization review board, and
- 10 any other state-administered health insurance program or its designee if
- any such entities have a current data-sharing agreement with the 11
- 12 statewide health information exchange described in section 71-2455, and
- if such release is in accordance with the privacy and security provisions 13
- of the federal Health Insurance Portability and Accountability Act of 14
- 15 1996, Public Law 104-191, and all regulations promulgated thereunder;
- 16 (e) Organizations which facilitate the interoperability and mutual
- 17 exchange of information among state prescription drug monitoring programs
- or state or regional health information exchanges; or 18
- (f) Electronic health record systems or pharmacy-dispensing software 19
- systems for the purpose of integrating prescription drug information into 20
- 21 a patient's medical record.
- 22 (8) The statewide health information exchange described in section
- 71-2455, in collaboration with the department, may release to patients 23
- 24 their prescription drug information collected pursuant to this section.
- 25 Upon request of the patient, such information may be released directly to
- the patient or a personal health record system designated by the patient 26
- 27 which has privacy protections at least as restrictive as those set forth
- 28 in this section and that has implemented and maintains the minimum
- safeguards required by subsection (6) of this section. 29
- 30 (9) The department, or the statewide health information exchange
- described in section 71-2455 in collaboration with the department, may 31

- 1 release data collected pursuant to this section for statistical, public
- 2 research, public policy, or educational purposes after removing
- 3 information which identifies or could reasonably be used to identify the
- 4 patient, prescriber, dispenser, or other person who is the subject of the
- 5 information.
- 6 (10) The statewide health information exchange described in section
- 7 71-2455 or the department may request and receive program information
- 8 from other prescription drug monitoring programs for use in the
- 9 prescription drug monitoring system in this state.
- 10 <u>(11) The statewide health information exchange described in section</u>
- 11 71-2455, in collaboration with the department, shall implement
- 12 <u>technological improvements to facilitate the secure collection of, and</u>
- 13 access to, prescription drug information in accordance with this section.
- 14 (12) (6) Before accessing the prescription drug monitoring system,
- 15 any user shall undergo training on the purpose of the system, access to
- 16 and proper usage of the system, and the law relating to the system,
- 17 including confidentiality and security of the prescription drug
- 18 monitoring system. Such training shall be administered by the statewide
- 19 health information exchange described in section 71-2455 which shall have
- 20 access to the prescription drug monitoring system for training and
- 21 administrative purposes. Users who have been trained prior to May 10,
- 22 2017, or who are granted access by an entity receiving prescription drug
- 23 <u>information pursuant to subsection (7) of this section,</u> are deemed to be
- 24 in compliance with the training requirement of this subsection.
- 25 (13) (7) For purposes of this section:
- 26 (a) Deliver or delivery means to actually, constructively, or
- 27 <u>attempt to transfer a drug or device from one person to another, whether</u>
- 28 or not for consideration;
- 29 (b) Department means the Department of Health and Human Services;
- 30 <u>(c)</u> (a) Designee means any licensed or registered health care
- 31 professional credentialed under the Uniform Credentialing Act designated

- 1 by a prescriber or dispenser to act as an agent of the prescriber or
- 2 dispenser for purposes of submitting or accessing data in the
- 3 prescription drug monitoring system and who is supervised by such
- 4 prescriber or dispenser;
- 5 <u>(d) Prescription drug or drugs (b) Dispensed prescription</u> means a
- 6 prescription drug or drugs dispensed by delivery delivered to the
- 7 ultimate user or caregiver by or pursuant to the lawful order of a
- 8 prescriber but does not include (i) the delivery of such prescription
- 9 drug for immediate use for purposes of inpatient hospital care or
- 10 emergency department care, (ii) the administration of a prescription drug
- 11 by an authorized person upon the lawful order of a prescriber, (iii) a
- 12 wholesale distributor of a prescription drug monitored by the
- 13 prescription drug monitoring system, or (iv) the dispensing to a nonhuman
- 14 patient of a prescription drug which is not a controlled substance listed
- 15 in Schedule II, Schedule III, Schedule IV, or Schedule V of section
- 16 28-405;
- 17 <u>(e) (c)</u> Dispenser means a person authorized in the jurisdiction in
- 18 which he or she is practicing to deliver a prescription <u>drug</u> to the
- 19 ultimate user <u>or caregiver</u> by or pursuant to the lawful order of a
- 20 prescriber;
- 21 (f) (d) Participant means an individual or entity that has entered
- 22 into a participation agreement with the statewide health information
- 23 exchange described in section 71-2455 which requires the individual or
- 24 entity to comply with the privacy and security protections set forth in
- 25 the provisions of the federal Health Insurance Portability and
- 26 Accountability Act of 1996, Public Law 104-191, and regulations
- 27 promulgated thereunder; and
- 28 (g) (e) Prescriber means a health care professional authorized to
- 29 prescribe in the profession which he or she practices.
- 30 Sec. 5. Original section 71-2454, Reissue Revised Statutes of
- 31 Nebraska, and sections 28-473, 28-474, and 38-101, Revised Statutes

LB556 2019 LB556 2019

- 1 Cumulative Supplement, 2018, are repealed.
- Sec. 6. Since an emergency exists, this act takes effect when
- 3 passed and approved according to law.